Parathyroid Disease Treatment Market Report 2026

The parathyroid disease treatment market size has grown strongly in recent years. It will grow from $2.37 billion in 2025 to $2.54 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of hyperparathyroidism, limited awareness of parathyroid disorders, dependence on conventional hormone replacement therapy, lack of advanced surgical interventions, constrained hospital pharmacy infrastructure.

The parathyroid disease treatment market size is expected to see strong growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing demand for calcimimetics and bisphosphonates, advancements in parathyroid imaging and diagnostics, growing homecare and telemedicine solutions, regulatory support for precision medicine, expanding specialty centers for endocrine disorders. Major trends in the forecast period include increasing adoption of calcimimetics and bisphosphonates, rising preference for parenteral over oral administration in severe cases, expansion of hospital and specialty care settings, growing focus on personalized hormone replacement therapies, integration of lifestyle and nutritional interventions in treatment plans.

The rising prevalence of chronic kidney disease (CKD) is expected to drive growth in the parathyroid disease treatment market in the coming years. Chronic kidney disease is a long-term condition in which the kidneys gradually lose their ability to function properly, causing imbalances in essential minerals such as calcium and phosphorus. The increasing prevalence of CKD is largely attributed to the growing incidence of diabetes, as prolonged high blood sugar levels can damage the kidneys’ filtering units over time, leading to diabetic nephropathy. Parathyroid disease treatments play a critical role in managing CKD by addressing secondary hyperparathyroidism, a common complication in advanced stages that disrupts calcium and phosphorus balance, contributes to bone disorders, and promotes vascular calcification. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, reported that more than one in seven US adults - approximately 35.5 million people, or 14% - had CKD in 2023, and nearly 90% of them were unaware of their condition. Therefore, the rising prevalence of chronic kidney disease is propelling growth in the parathyroid disease treatment market.

Key companies in the parathyroid disease treatment market are focusing on developing innovative therapies such as parathyroid hormone (PTH) prodrugs to improve calcium regulation and reduce dosing frequency in patients with hypoparathyroidism. PTH prodrugs are inactive compounds that convert into active parathyroid hormone in the body to restore calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), a PTH [1-34] prodrug for treating chronic hypoparathyroidism in adults. This once-daily therapy provides continuous parathyroid hormone exposure over 24 hours, offering an alternative to conventional calcium and vitamin D supplementation by directly addressing the underlying hormone deficiency. The approval of YORVIPATH highlights the growing emphasis on advanced hormone replacement therapies designed to improve adherence and clinical outcomes for patients with parathyroid disorders.

In July 2024, AstraZeneca PLC, a UK-based biopharmaceutical company, acquired Amolyt Pharma SAS for $1.05 billion. Through this acquisition, AstraZeneca aims to strengthen its Alexion Rare Disease portfolio by advancing its late-stage pipeline and expanding its bone metabolism franchise with eneboparatide (AZP-3601), a Phase III investigational therapy for hypoparathyroidism. Amolyt Pharma SAS is a France-based clinical-stage biotechnology company developing novel treatments for rare endocrine diseases, including parathyroid disorders such as hypoparathyroidism.

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the parathyroid disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the parathyroid disease treatment market by increasing costs for imported active pharmaceutical ingredients (APIs) and medical devices used in parathyroid therapies. The resulting price surge is affecting segments such as calcimimetics, bisphosphonates, and parenteral administration, particularly in North America and Europe, where imports constitute a significant portion of the supply chain. Hospitals and specialty centers are most affected due to procurement dependence on global suppliers. However, tariffs are also encouraging local manufacturing and innovation, potentially reducing long-term dependency on imports and boosting domestic production capabilities.

The parathyroid disease treatment market research report is one of a series of new reports that provides parathyroid disease treatment market statistics, including parathyroid disease treatment industry global market size, regional shares, competitors with a parathyroid disease treatment market share, detailed parathyroid disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the parathyroid disease treatment industry. This parathyroid disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Parathyroid disease treatment refers to medical and surgical interventions used to manage disorders of the parathyroid glands, which are small endocrine glands located in the neck that regulate calcium and phosphorus levels in the body through the secretion of parathyroid hormone (PTH).

The main types of parathyroid disease treatment include calcimimetics, bisphosphonates, plicamycin, hormone replacement therapy, and other therapies. Calcimimetics are drugs that lower PTH levels by mimicking calcium and activating calcium-sensing receptors on the parathyroid glands. These treatments are administered through various routes, including oral and parenteral, and are distributed via hospital pharmacies, retail pharmacies, and online pharmacies. They are used by a range of end users, including hospitals, homecare settings, specialty centers, and others.

The parathyroid disease treatment market consists of revenues earned by entities by providing services such as diagnostic testing, surgical intervention, hormone level monitoring, post-operative care, and medical management of calcium and phosphate balance. The market value includes the value of related goods sold by the service provider or included within the service offering. The parathyroid disease treatment market also includes sales of lanthanum carbonate, doxercalciferol, calcitriol, lanthanum carbonate, and parsabiv. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.